Spatial training decreases the association between Ndfip1 and Nedd4 and decreases endogenous Beclin 1 ubiquitination in the hippocampus. by Wei-Lun Hsu (1756123)

“…Endogenous Beclin 1 ubiquitination level is decreased in Nedd4 siRNA-transfected rats (t_1,6 = 5.78, <i>p</i> = 0.001). …”

Botulinum toxin A (3.5 U/kg) decreases mechanical allodynia induced by IoNC- injury in rats. by Boris Filipović (336089)

A long-term "memory" of HIF induction in response to chronic mild decreased oxygen after oxygen normalization-5 by Chandrashekhar D Kamat (60176)

“…<p><b>Copyright information:</b></p><p>Taken from "A long-term "memory" of HIF induction in response to chronic mild decreased oxygen after oxygen normalization"</p><p>BMC Cardiovascular Disorders 2007;7():4-4.…”

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Decreased cellular infiltration into lungs of <i>Ifi35</i> deficient mice after H5N1-VN/PR8 infection. by Anshu P. Gounder (626041)

Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…CRT in the recurrence group significantly decreased from 546.1 ± 117.0 μm preoperatively to 317.1 ± 46.9, 317.8 ± 55.6, 290.8 ± 33.5, 342.9 ± 82.2, 333.0 ± 84.2, and 349.8 ± 76.9 μm at 1, 3, 6, 12, 24, and 36 months postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”

SARS-CoV-2 decreases excitatory synapses, while influenza A does not induce cell death in BCO. by Pinar Mesci (14053895)

Absence of PML decreases the co-localization of DAXX and ATRX but not HIRA and UBN1 with latent/quiescent HSV-1 genomes. by Camille Cohen (2440810)

Relative Aggrecan mRNA expression levels, as measured by qPCR, in lentiviral-transduced control cells and 5 AggKD cell lines confirm decreased Aggrecan expression in the AggKD cell... by Juanita K. Hodax (6848540)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects: